| Literature DB >> 19751585 |
Jennifer R Verani1, Suchita A Lorick, Jonathan S Yoder, Michael J Beach, Christopher R Braden, Jacquelin M Roberts, Craig S Conover, Sue Chen, Kateesha A McConnell, Douglas C Chang, Benjamin J Park, Dan B Jones, Govinda S Visvesvara, Sharon L Roy.
Abstract
An outbreak of Acanthamoeba keratitis, a rare, potentially blinding, corneal infection, was detected in the United States in 2007; cases had been increasing since 2004. A case-control study was conducted to investigate the outbreak. We interviewed 105 case-patients from 30 states and 184 controls matched geographically and by contact lens use. Available contact lenses, cases, solutions, and corneal specimens from case-patients were cultured and tested by molecular methods. In multivariate analyses, case-patients had significantly greater odds of having used Advanced Medical Optics Complete Moisture Plus (AMOCMP) solution (odds ratio 16.9, 95% confidence interval 4.8-59.5). AMOCMP manufacturing lot information was available for 22 case-patients, but none of the lots were identical. Three unopened bottles of AMOCMP tested negative for Acanthamoeba spp. Our findings suggest that the solution was not intrinsically contaminated and that its anti-Acanthamoeba efficacy was likely insufficient. Premarket standardized testing of contact lens solutions for activity against Acanthamoeba spp. is warranted.Entities:
Mesh:
Substances:
Year: 2009 PMID: 19751585 PMCID: PMC2815976 DOI: 10.3201/eid1508.090225
Source DB: PubMed Journal: Emerg Infect Dis ISSN: 1080-6040 Impact factor: 6.883
Figure 1Acanthamoeba keratitis case-patients by state, USA (N = 105). *Number of interviewed case-patients per state. Because of incomplete case reporting and enrollment in case–control study, incidence rates were not calculated.
Figure 2Symptom onset of cases of Acanthamoeba keratitis, by month and year, United States, 2005–2007 (N = 105).
Demographic and clinical characteristics of 105 patients with Acanthamoeba keratitis, United States, 2005–2007
| Characteristic | No. (%) |
|---|---|
| Sex | |
| Female | 67 (64) |
| Age, y* | |
| 12–17 | 27 (26) |
| 18–24 | 17 (16) |
| 25–34 | 15 (14) |
| 35–49 | 24 (23) |
| 22 (21) | |
| Contact lens wear | |
| Did not use contact lenses | 12 (11) |
| Used contact lenses | 93 (89) |
| Lens type | |
| Soft lenses | 82 (88) |
| Rigid lenses | 10 (11) |
| Hybrid lenses | 1 (1) |
| Contact lens solution use among contact users† | |
| Did not use cleaning or disinfecting contact lens solution | 6 (6) |
| Used any type of cleaning or disinfecting contact lens solution | 87 (94) |
| Type of solution used§ | |
| Multipurpose solution | 78 (90) |
| Hydrogen peroxide solution | 6 (7) |
| Daily cleaner | 11 (13) |
| Affected eye | |
| Right | 53 (50) |
| Left | 44 (42) |
| Both | 8 (8) |
| Symptoms when treatment sought‡§ | |
| Pain | 78 (74) |
| Redness | 78 (74) |
| Sensitivity to light | 76 (72) |
| Sensation of foreign body | 71 (68) |
| Increased tearing | 59 (56) |
| Blurred vision | 57 (54) |
| Discharge from eye | 20 (19) |
| Clinical status¶ | |
| Resolved with pharmacologic therapy | 32 (38) |
| Currently receiving pharmacologic therapy | 29 (34) |
| Corneal transplant performed | 21 (25) |
| Corneal transplant planned | 3 (4) |
| Most recent visual acuity with best correction in affected eye# | |
| 20/20 | 17 (24) |
| 20/25–20/100 | 24 (34) |
| 20/ | 29 (41) |
*Median 29 y, range 12–76 y. †During 1 month before illness onset; n = 93. ‡Not mutually exclusive. §Median time from symptom onset to anti-Acanthamoeba therapy (n = 80) was 49 d (range 4–197 d). ¶At the time of treating ophthalmologist interview; n = 85. #At the time of treating ophthalmologist interview; n = 70.
Figure 3Matching of case-patients with Acanthamoeba keratitis and controls, United States, 2005–2007.
Multivariate analysis of demographic characteristics and exposures among 72 Acanthamoeba keratitis case-patients and 140 controls who used soft contact lenses, United States, 2005–2007*
| Demographic characteristic or exposure† | No. (%) case-patients, n = 72 | No. (%) controls, n = 140 | Adjusted matched OR (95% CI)‡ |
|---|---|---|---|
| AMOCMP | 40 (55.6) | 15 (10.7) | 16.9 (4.8–59.5) |
| Ever top off or reuse old solution in case | 40 (57.1) | 30 (22.7) | 2.8 (1.2–6.8) |
| 37 (51.4) | 32 (22.9) | 2.8 (1.0–7.6) |
*OR, odds ratio; CI, confidence interval; AMOCMP, Advanced Medical Optics Complete MoisturePlus. †During 1mo before symptom onset. Missing values excluded from analysis. ‡Adjusted for age and sex. p<0.05.